Key Takeaways Starting dose: 2 mg once weekly for 4 weeks Titration pace: Increase every 4 weeks: 2 4 8 12 mg Maximum dose: 12 mg weekly (Phase 2/3 clinical trial protocol) Total ramp-up: ~16 weeks to reach maximum dose Mechanism: Triple agonist (GLP-1 + GIP + Glucagon), the only triple-agonist in late-stage trials Weight loss: Up to 24.2% at 48 weeks (Phase 2) and 28.7% at 68 weeks (Phase 3 TRIUMPH-4) GLP-3 Retatrutide Dosage Chart Free printable reference chart showing the retatrutide (GLP-3) clinical trial titration schedule from 2 mg to 12 mg weekly
Ozempic is commonly prescribed to patients for the treatment of type 2 diabetes and has also demonstrated effectiveness in supporting healthy weight management
The free tier will launch before the end of the summer and deliver a personalized experience focused on building healthy habits in nutrition, physical activity, and stress reduction
It had all the components I was looking for, and most importantly, I never felt like I was left on my own
MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults
Talking to Your Doctor About New Weight Loss Medicines Patients interested in new weight loss treatments should speak to their GP about currently approved options such as semaglutide (Wegovy) or enquire about clinical trial eligibility through the NIHR 'Be Part of Research' website
